This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Donahue KE et al. (2008) Systematic review: comparative effectiveness and harms of disease-modifying medications for rheumatoid arthritis. Ann Intern Med 148: 124–134
Feinstein AR (1983) An additional basic science for clinical medicine: II. The limitations of randomized trials. Ann Intern Med 99: 544–550
Pincus T and Sokka T (2004) Clinical trials in rheumatic diseases: designs and limitations. Rheum Dis Clin North Am 30: 701–724
Felson DT et al. (1990) The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis. Results of two metaanalyses. Arthritis Rheum 33: 1449–1461
Pincus T et al. (1992) Long-term drug therapy for rheumatoid arthritis in seven rheumatology private practices: II. Second-line drugs and prednisone. J Rheumatol 19: 1885–1894
Yazici Y et al. (2005) Long term safety of methotrexate in routine clinical care: discontinuation is unusual and rarely the result of laboratory abnormalities. Ann Rheum Dis 64: 207–211
Sokka T and Pincus T (2003) Most patients receiving routine care for rheumatoid arthritis in 2001 did not meet inclusion criteria for most recent clinical trials or American College of Rheumatology criteria for remission. J Rheumatol 30: 1138–1146
Pincus T et al. (2005) Patients seen for standard rheumatoid arthritis care have significantly better articular, radiographic, laboratory, and functional status in 2000 than in 1985. Arthritis Rheum 52: 1009–1019
Duclos M et al. (2006) Retention rates of tumor necrosis factor blockers in daily practice in 770 rheumatic patients. J Rheumatol 33: 2433–2438
Sokka T et al. (2008) Treatment of rheumatoid arthritis. A global perspective of the use of antirheumatic drugs. Mod Rheumatol, in press
Puolakka K et al. (2005) Early suppression of disease activity is essential for maintenance of work capacity in patients with recent-onset rheumatoid arthritis: five-year experience from the FIN-RACo trial. Arthritis Rheum 52: 36–41
Grigor C et al. (2004) Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 364: 263–269
Goekoop-Ruiterman YP et al. (2005) Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 52: 3381–3390
Verstappen SMM et al. (2007) Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). Ann Rheum Dis 66: 1443–1449
Wolfe F and Michaud K (2007) Resistance of rheumatoid arthritis patients to changing therapy. Arthritis Rheum 56: 2135–2142
Smith GC and Pell JP (2003) Parachute use to prevent death and major trauma related to gravitational challenge: systemic review of randomised controlled trials. BMJ 327: 1459–1461
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
T Pincus is a consultant for Bristol-Myers Squibb and Amgen, and has received grants/research support from Bristol-Myers Squibb and Amgen. The other authors declared no competing interests.
Rights and permissions
About this article
Cite this article
Pincus, T., Yazici, Y. & Sokka, T. Are excellent systematic reviews of clinical trials useful for patient care?. Nat Rev Rheumatol 4, 294–295 (2008). https://doi.org/10.1038/ncprheum0812
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ncprheum0812